Curis(CRIS) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Curis reported a net income of $19.4 million or $1.23 per share for Q4 2025, compared to a net loss of $9.6 million or $1.25 per share for Q4 2024, primarily due to a $27.2 million one-time non-cash gain from the sale of Erivedge [10] - For the year ended December 31, 2025, the net loss was $7.6 million or $0.58 per share, a significant improvement from a net loss of $43.4 million or $6.88 per share in 2024 [10] - Research and development expenses decreased to $5.8 million in Q4 2025 from $9 million in Q4 2024, and for the year, they were $28.3 million compared to $38.6 million in 2024 [11] - General and administrative expenses also decreased to $2.9 million in Q4 2025 from $3.4 million in Q4 2024, totaling $14 million for the year compared to $16.8 million in 2024 [11] Business Line Data and Key Metrics Changes - The Take Aim Lymphoma study in primary CNS lymphoma is progressing well, with expectations for accelerated submissions in the U.S. and Europe [4] - Initial data from the ongoing AML triplet study showed that 5 of 8 evaluable patients achieved MRD conversion, indicating potential effectiveness of the treatment combination [8][9] Market Data and Key Metrics Changes - The company is focusing on expanding emavusertib studies into additional NHL subtypes, particularly CLL, where current treatments have limitations [5][6] - The company is prioritizing NHL studies over AML due to resource allocation and the potential for registrational approval in PCNSL [14][15] Company Strategy and Development Direction - Curis aims to improve the treatment paradigm for CLL by combining emavusertib with BTKI regimens, targeting deeper responses and potential complete remission [6][39] - The company is actively engaging with clinical sites in the U.S. and Europe to advance its studies and expects to present initial data at the ASH annual meeting in December [7][9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the progress in clinical trials and the potential for significant advancements in treatment options for patients with CLL and NHL [4][9] - The company anticipates no meaningful revenue in 2026 due to the cessation of cash flows from Erivedge, but is confident in its financial position to support operations into the second half of 2027 [12][27] Other Important Information - Curis has secured initial gross proceeds of $20.2 million from financing, which will support its operations and clinical trials [12] Q&A Session Summary Question: How is the company prioritizing trial progress between pivotal PCNSL versus CLL and AML? - Management indicated that resources are being prioritized towards NHL, particularly PCNSL, while CLL is in the early stages of study [14][15] Question: Can you provide updates on PCNSL enrollment? - Management confirmed that enrollment is on track, with expectations for full enrollment within 12-18 months [22] Question: Should revenue modeling reflect no meaningful revenue for 2026? - Management confirmed that there will be no meaningful revenue, as cash flows from Erivedge have ended [27][28] Question: What data should be expected at ASH 2026 for CLL? - Management stated that they hope to present meaningful data regarding the treatment's effectiveness, focusing on deepening patient responses [35][36]